Synlett 2012; 23(12): 1816-1820
DOI: 10.1055/s-0031-1290397
letter
© Georg Thieme Verlag Stuttgart · New York

Synthesis of 3-Substituted 2-Aminopyridines via Displacement of 3-Fluoro-2-nitropyridine

Janet D. Culshaw
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
,
Jonathan M. Eden*
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
,
Susannah J. Ford
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
,
Barry Hayter
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
,
David R. Perkins*
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
,
Kurt G. Pike
Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK, Email: jonathan.eden@astrazeneca.com   Email: dave.perkins@astrazeneca.com
› Author Affiliations
Further Information

Publication History

Received: 06 March 2012

Accepted after revision: 01 May 2012

Publication Date:
21 June 2012 (online)


Abstract

An efficient method for the substitution of 3-fluoro-2-nitropyridine with a range of nitrogen-containing heterocycles and aliphatic amines is described. The reaction proceeds in a regioselective manner at moderate temperature and in reasonable yield.

Supporting Information

 
  • References and Notes

  • 1 Singh OM, Singh SJ, Kim SN, Lee S. Bull. Korean Chem. Soc. 2007; 28: 115
  • 2 Inglis SR, Jones RK, Booker GW, Pyke SM. Bioorg. Med. Chem. Lett. 2006; 16: 387
  • 3 Mathes BM, Hudziak KJ, Schaus JM, Xu Y, Nelson DL, Wainscott DB, Nutter SE, Gough WH, Branchek TA, Zgombick JM, Filla SA. Bioorg. Med. Chem. Lett. 2004; 14: 167
  • 4 Richards ML, Lio SC, Sinha A, Banie H, Thomas RJ, Major M, Tanji M, Sircar JC. Eur. J. Med. Chem. 2006; 41: 950
  • 5 Huang KS, Haddadin MJ, Kurth MJ. J. Org. Chem. 2002; 67: 2382
  • 6 Ravina I, Zicane D, Petrova M, Gudriniece E, Kalejs U. Chem. Heterocycl. Compd. 2002; 38: 836
  • 7 Cocco MT, Congiu C, Onnis V. Chem. Pharm. Bull. 2001; 49: 703
  • 8 Gueiffier A, Viols H, Blache Y, Chapat JP, Chavignon O, Teulade JC, Fauvelle F, Grassy G, Dauphin G. J. Heterocycl. Chem. 1997; 34: 765
  • 9 Yamamoto H, Matsuura M, Ikeda H, Kubota M, Kawamura M. EP 158516A1, 2005
  • 10 Koubachi J, El Kazzouli S, Berteina-Raboin S, Mouaddib A, Guillaumet G. J. Org. Chem. 2007; 72: 7650
  • 11 Almario-Garcia A, Lardeenois P, Olivier A. US 2009/0253735A1, 2009
  • 12 Wu Z, Fraley ME, Bilodeau MT, Kaufman ML, Tasber ES, Balitza AE, Hartman GD, Coll KE, Rickert K, Shipman J, Shi B, Sepp-Lorenzino L, Thomas KA. Bioorg. Med. Chem. Lett. 2004; 14: 909
  • 13 Dubey PK, Kumar RV. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2000; 39: 746
  • 14 Sharma AK, Das SK. Synth. Commun. 2004; 34: 3807
  • 15 Sarkis GY, Faisal ED. J. Heterocycl. Chem. 1985; 22: 137
  • 16 Andrews K, Booker S, Cee VJ, D’Angelo N, Herberich BJ, Hong F, Jackson CL. M, Lanman B, Liao H, Liu L, Nishimura N, Norman MH, Pettus LH, Reed AB, Smith AL, Tadesse S, Tamayo NA, Wu B, Wurz R. WO 2010/126895A1, 2010
  • 17 Blankley CJ, Doherty AM, Hamby JM, Panek RL, Schroeder MC, Showalter HD. H, Connolly C. US 5733913A1, 1998
  • 18 Balicki R, Kaczmarek L, Sobotka W. J. Prakt. Chem. 1989; 331: 995
  • 19 Yao J, Blake PR, Yang J. Heterocycles 2005; 65: 2071
  • 20 Azev YA, Mokrushina GA, Postovskii IY. Chem. Heterocycl. Compd. 1974; 10: 687
  • 21 Typical Procedure for the Preparation of Nitropyridines Illustrated for Table 2, entry 1: K2CO3 (5.15 g, 37.23 mmol) was added in one portion to 3-fluoro-2-nitropyridine (2.65 g, 18.62 mmol) and 4-chloro-1H-pyrazole (2.00 g, 19.55 mmol) in MeCN (50 mL), and the resulting mixture was stirred at 50 °C for 5 h. The cooled reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (2 × 50 mL). The combined extracts were washed with brine (100 mL), dried (MgSO4), filtered, and evaporated. The crude product was purified by flash silica chromatography, elution gradient 30% to 60% CH2Cl2 in heptane. Pure fractions were evaporated to dryness to afford 3-(4-chloro-1H-pyrazol-1-yl)-2-nitropyridine (2.40 g, 57%) as a solid; mp 113–114 °C. 1H NMR (400 MHz, CDCl3): δ = 8.54 (1 H, dd, J = 4.6, 1.5 Hz), 8.07 (1 H, dd, J = 8.1, 1.5 Hz), 7.75 (1 H, s), 7.69–7.73 (2 H, m). 13C NMR (101 MHz, CDCl3): δ = 114.28, 127.41, 128.00, 128.21, 134.85, 141.77, 147.32, 189.75. HRMS (ES): m/z calcd for (C8H5N4O2Cl)+: 224.0101; found: 224.0103. Typical Procedure for the Reduction of Nitropyridines Using Method A A suspension of the nitropyridine (2.06 mmol) and 10% Pd/C (0.03 mmol) in EtOH (20 mL)–EtOAc (3 mL) was stirred under an atmosphere of hydrogen at ambient temperature for 16 h. The reaction mixture was filtered through Celite, evaporated and the crude gum triturated with Et2O–heptane to give a solid, which was collected by filtration and dried under vacuum to give the aminopyridine. Typical Procedure for the Reduction of Nitropyridines Using Method B Illustrated for Table 2, entry 1: NH4Cl (2.70 g, 50.53 mmol) was added to 3-(4-chloro-1H-pyrazol-1-yl)-2-nitropyridine (2.27 g, 10.11 mmol) and iron (3.61 g, 64.64 mmol) in EtOH (30 mL) and H2O (5 mL), and the resulting mixture was stirred at 80 °C for 3 h. The solvent was evaporated, and the crude product was slurried with MeOH and filtered through a Whatman No. 3 filter paper before purification by ion-exchange chromatography, using an SCX 2 column. The desired product was eluted from the column using 2 M NH3–MeOH, and pure fractions were evaporated to dryness to afford crude product. The product was dissolved in CH2Cl2 and washed with H2O (2×). The organic layer was dried over Mg2SO4, filtered, and evaporated to afford 3-(4-chloro-1H-pyrazol-1-yl)pyridin-2-amine (1.17 g, 59%) as a solid; mp 134–135.6 °C. 1H NMR (400 MHz, DMSO): δ = 8.44 (1 H, s), 8.03 (1 H, dd, J = 4.8, 1.6 Hz), 7.89 (1 H, s), 7.62 (1 H, dd, J = 7.7, 1.6 Hz), 6.70 (1 H, dd, J = 7.7, 4.8 Hz), 6.32 (2 H, s). 13C NMR (101 MHz, DMSO, 30 °C): δ = 110.07, 112.24, 120.09, 128.98, 131.43, 138.69, 147.44, 152.81. HRMS (ES): m/z calcd for [C8H8N4Cl]+: 195.0432; found: 195.0431